Addex Therapeutics Ltd. (ADXN)

Addex Therapeutics is a clinical-stage pharmaceutical company built on a singular technological foundation: allosteric modulation of GABA and glutamate receptors in the central nervous system. The company controls discovery and development platforms that identify small molecule drugs capable of modulating—rather than blocking or fully activating—their neurological targets, a distinction that matters because allosteric compounds can be exquisitely selective and often avoid the side effects that plague traditional orthosteric drugs (direct-binding molecules that occupy the primary site).

Founded in 2002 and headquartered in Geneva, Addex has grown not through acquisitions but through disciplined focus on one therapeutic chemistry: the allosteric modulator landscape. The company maintains a portfolio of programs in various stages of clinical development, each aimed at neurological or neuropsychiatric disorders where precision and tolerability are the limiting factors in existing treatment options. Its intellectual property position rests on deep know-how in screening, characterization, and optimization of allosteric compounds—work that requires years of biochemistry, not just compound libraries.

Partnership and capital flow represent the company’s financial model. Addex has granted licenses to larger pharma partners, notably Janssen Pharmaceuticals (for mGlu2 PAM compounds in certain indications) and Indivior PLC (for GABAB PAM compounds in addiction and related CNS disorders). These agreements provide both upfront payments and milestone-driven revenue, reducing the company’s need to fully fund development of every asset. Addex also invests in adjacent precision-medicine opportunities—in 2025 it led a CHF 2 million round in Stalicla, a neurodevelopmental disorder company—signaling confidence in the broader neurological market and willingness to diversify revenue streams beyond its core pipeline.

The company trades on both the SIX Swiss Exchange and NASDAQ under the single ticker ADXN, a dual listing that reflects both its Swiss domicile and its capital markets access. As a clinical-stage operator, Addex’s value is entirely forward-looking: tied to the success of its pipeline, the strength of its IP, and the partnerships it cultivates with larger players who can take compounds into late-stage trials and commercialization. The allosteric modulator class remains unproven at scale in the market, but the scientific rationale is sound and the clinical-stage status leaves room for milestone achievements to drive investor narrative shifts.